ReutersCodex · 实盘不做把握 5/10
北京时间·🕒 发布 07:02:42时区推断·⟳ 抓取 10:56:04·⚡ 决策 07-02 12:01:40 +1h05m·117.2 天前
Abivax超额完成8亿美元融资，估值接近110亿美元但短期出售压力下降
8亿美元ADS增发由600亿美元上调且定价125美元，高于三日VWAP，说明机构需求强并把现金 runway 延长至2029年二季度。
📄 原文Reuters↗ 原文
Abivax SA raised $800 million in an expanded share sale on Wednesday after strong investor demand, valuing the French…
不做 Abivax（ABVX.US）
Abivax（ABVX.US）融资和安全性修复虽正向，但已在6月30日至7月1日公开传播并伴随近20日82.8%涨幅；Reuters新增的“降低出售压力”还削弱近端并购溢价，当前不具备正期望追多。
不做 Abivax（ABVX.FR）
Abivax（ABVX.FR）虽为同一公司普通股，但本次档案未提供可用FR行情，不能给可回测买入价格；且核心催化已在ADR端充分传播。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
关键理由
- 8亿美元ADS增发由600亿美元上调且定价125美元，高于三日VWAP，说明机构需求强并把现金 runway 延长至2029年二季度。
- 但ABVX.US近5日已涨43.3%、近20日已涨82.8%，本轮信息链从6月30日融资启动、7月1日定价和安全性数据已经公开传播，Reuters的M&A压力缓解更多是事后解读。
- 融资缓解现金压力同时也降低近端被收购的紧迫性，对以并购预期定价的生物科技股并非单向利好，且仍有obefazimod肿瘤安全性质疑。
主要风险
- 若后续大型药企仍推进收购或FDA沟通明显积极，ABVX.US可能继续挤压空头并创高。
- obefazimod肿瘤事件虽被公司解释为与治疗无关，但若监管或外部专家不认可，当前高估值回撤风险很大。
原文全文
展开原文 · 2,971 字
Abivax SA raised $800 million in an expanded share sale on Wednesday after strong investor demand, valuing the French biotechnology company at nearly $11 billion and easing pressure to pursue a near-term sale.
Abivax, which is developing treatments for chronic inflammatory diseases including ulcerative colitis and Crohn's disease, has long been viewed by investors and industry executives as a potential takeover target for larger drugmakers seeking to build their inflammation and immunology businesses.
The company's lead drug candidate, obefazimod, is in late-stage, Phase 3 testing. The capital raise is enough to fund research and operations until the second quarter of 2029, the company said in a statement.
A sale remains possible, but the financing gives Abivax greater strategic flexibility and removes the time pressure that often accompanies biotech deal talks, a person familiar with the matter said.
Abivax increased the size of its offering by a third, from $600 million to $800 million, as orders exceeded the shares available, the company said in a statement.
CANCER CASES OVERSHADOW TRIAL RESULTS
Abivax U.S. listed shares closed at $132.56 on the Nasdaq on Wednesday after falling as low as $72.50 last month, following investor concerns over cancer cases reported in the trial.
Positive Phase 3 results for obefazimod disclosed on June 1 were overshadowed by reports of seven malignancy cases among 195 patients receiving the 50-mg dose. Abivax said investigators considered the cases unrelated to treatment.
The uncertainty led some pharmaceutical companies to wait for additional safety data before pursuing any potential transaction, two people close to the discussions said.
The decision to raise capital followed talks with potential buyers in mid-June, when the company's market capitalization was about $7 billion, said a second person, who requested anonymity because the information is private.
On Tuesday, Abivax reported additional Phase 3 maintenance data that helped alleviate some of the concerns that had weighed on the shares earlier in the month.
OFFERING PRICED AT PREMIUM
The drug developer is selling 6.4 million American Depositary Shares (ADSs), each representing one ordinary share, at $125 apiece.
The offering was priced at a 2.39% premium to the stock’s three-day volume-weighted average price, reflecting strong demand.
The company has also granted underwriters an option to buy up to 960,000 additional ADSs, or 15% of the deal, which could lift total proceeds to about $920 million if exercised in full.
Abivax said it plans to use the proceeds to fund the potential commercialization of its lead drug candidate, obefazimod, in the United States, as well as clinical development in ulcerative colitis and Crohn’s disease.
Leerink Partners, Morgan Stanley, Piper Sandler and Guggenheim Securities are acting as joint bookrunners on the transaction. Law firm Cooley also advised Abivax.
Abivax, which is developing treatments for chronic inflammatory diseases including ulcerative colitis and Crohn's disease, has long been viewed by investors and industry executives as a potential takeover target for larger drugmakers seeking to build their inflammation and immunology businesses.
The company's lead drug candidate, obefazimod, is in late-stage, Phase 3 testing. The capital raise is enough to fund research and operations until the second quarter of 2029, the company said in a statement.
A sale remains possible, but the financing gives Abivax greater strategic flexibility and removes the time pressure that often accompanies biotech deal talks, a person familiar with the matter said.
Abivax increased the size of its offering by a third, from $600 million to $800 million, as orders exceeded the shares available, the company said in a statement.
CANCER CASES OVERSHADOW TRIAL RESULTS
Abivax U.S. listed shares closed at $132.56 on the Nasdaq on Wednesday after falling as low as $72.50 last month, following investor concerns over cancer cases reported in the trial.
Positive Phase 3 results for obefazimod disclosed on June 1 were overshadowed by reports of seven malignancy cases among 195 patients receiving the 50-mg dose. Abivax said investigators considered the cases unrelated to treatment.
The uncertainty led some pharmaceutical companies to wait for additional safety data before pursuing any potential transaction, two people close to the discussions said.
The decision to raise capital followed talks with potential buyers in mid-June, when the company's market capitalization was about $7 billion, said a second person, who requested anonymity because the information is private.
On Tuesday, Abivax reported additional Phase 3 maintenance data that helped alleviate some of the concerns that had weighed on the shares earlier in the month.
OFFERING PRICED AT PREMIUM
The drug developer is selling 6.4 million American Depositary Shares (ADSs), each representing one ordinary share, at $125 apiece.
The offering was priced at a 2.39% premium to the stock’s three-day volume-weighted average price, reflecting strong demand.
The company has also granted underwriters an option to buy up to 960,000 additional ADSs, or 15% of the deal, which could lift total proceeds to about $920 million if exercised in full.
Abivax said it plans to use the proceeds to fund the potential commercialization of its lead drug candidate, obefazimod, in the United States, as well as clinical development in ulcerative colitis and Crohn’s disease.
Leerink Partners, Morgan Stanley, Piper Sandler and Guggenheim Securities are acting as joint bookrunners on the transaction. Law firm Cooley also advised Abivax.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。